SRTA
Strata Critical Medical, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
6.24
▲ 0.28 (4.70%)
MARKET · —
Price
Open
6.13
Prev close
5.96
Day high
6.29
Day low
6.01
Volume
1.04M
Market cap
$552.03M
P/E (TTM)
—
52W range
3.85 – 6.50
Trailing performance
Returnvs SPY
1W
+5.76%
+7.1%
1M
+22.59%
+18.9%
3M
+7.59%
+4.5%
6M
+38.67%
+27.6%
YTD
+29.73%
+17.4%
1Y
+51.09%
+31.1%
3Y
+77.78%
+3.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$552.03M
Enterprise value$533.53M
Revenue (TTM)$255.98M
Gross profit$54.40M
EBITDA$7.22M
Net income$-23.16M
EPS (TTM)$-0.28
Free cash flow$-20.09M
Total cash$22.75M
Total debt$4.25M
Book value / share$3.16
Shares outstanding88.47M
Float58.22M
Short % of float6.02%
Dividend yield—
Beta (5Y)2.25
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book1.98
EV / revenue2.08
EV / EBITDA73.88
Gross margin21.25%
Operating margin-6.32%
Profit margin15.71%
Return on equity-9.22%
Return on assets-1.86%
Debt / equity1.52
Current ratio2.64
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $197.14M | $248.69M | $225.18M | $146.12M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $41.35M | -$27.31M | -$56.08M | -$27.26M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $41.35M | -$27.31M | -$56.08M | -$27.26M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.02 | -0.12 | -500.0% |
| Mar 2026 | -0.04 | 0.04 | +212.0% |
| Dec 2025 | -0.01 | -0.06 | -500.0% |
| Sep 2025 | -0.02 | -0.12 | -500.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.01 | 4 | $72.67M | +47.4% |
| Next quarter | 0.01 | 4 | $78.26M | +17.2% |
| Current year | -0.09 | 4 | $290.80M | +47.5% |
| Next year | 0.00 | 3 | $326.10M | +12.1% |
Analyst targets & ownership
Mean target$9.56
High target$12.75
Low target$8.00
Implied upside53.25%
Analyst count4
ConsensusNONE
Strong buy / Buy0 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders14.22%
Held by institutions71.77%
Institutions holding186
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+2.41M
Net buying
Buy transactions
16
2.55M shares
Sell transactions
7
141.88K shares
Net transactions
+23
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
12.58M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 10, 26 | LOVE REGINALD LAMONTE Director |
SELL | 5.09K | $29.27K | Direct |
| Jul 30, 26 | PHILIP EDWARD M Director |
STOCK | 30.91K | $0 | Direct |
| Jul 30, 26 | HEYBURN WILLIAM A Chief Executive Officer |
STOCK | 360.23K | $0 | Direct |
| Jul 30, 26 | TOMKIEL MELISSA M. Chief Executive Officer |
STOCK | 415.88K | $0 | Direct |
| Jul 30, 26 | COHEN AMIR Officer |
STOCK | 69.21K | $0 | Direct |
| Jul 30, 26 | LAUCK ANDREW Director |
STOCK | 35.26K | $0 | Direct |
| Jul 30, 26 | WUNSCH SCOTT M Officer |
STOCK | 57.17K | $0 | Direct |
| Jul 30, 26 | COOK WILLIAM L III Director |
STOCK | 44.44K | $0 | Direct |
| Jul 30, 26 | WIESENTHAL ROBERT S Director |
STOCK | 50.23K | $0 | Direct |
| Jul 30, 26 | LOVE REGINALD LAMONTE Director |
STOCK | 37.67K | $0 | Direct |
| Jun 8, 26 | HEYBURN WILLIAM A Chief Executive Officer |
SELL | 31.67K | $185.91K | Direct |
| Jun 8, 26 | TOMKIEL MELISSA M. Chief Executive Officer |
SELL | 29.73K | $174.51K | Direct |
| Jun 8, 26 | COHEN AMIR Officer |
SELL | 4.66K | $27.32K | Direct |
| Jun 8, 26 | WUNSCH SCOTT M Officer |
SELL | 5.55K | $32.58K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AFFELDT ERIC L |
Director | 581.21K | Stock Award(Grant) |
BORTHWICK JOHN |
Director | 203.98K | Stock Award(Grant) |
HEYBURN WILLIAM A |
Chief Executive Officer | 1.71M | Stock Award(Grant) |
LERER KENNETH B |
Director | 254.59K | Stock Award(Grant) |
LYNE SUSAN M |
Director | 187.19K | Stock Award(Grant) |
PHILIP EDWARD M |
Director | 265.08K | Stock Award(Grant) |
TOMKIEL MELISSA M. |
Chief Executive Officer | 2.10M | Stock Award(Grant) |
VERDETTO LOUIS R |
Officer | 1.27M | Stock Award(Grant) |
WIESENTHAL ROBERT S |
Director | 5.33M | Stock Award(Grant) |
WUNSCH SCOTT M |
Officer | 1.05M | Stock Award(Grant) |
Moving averages & technicals
SMA 10
5.96
+4.77% from price
SMA 20
5.66
+10.33% from price
SMA 50
5.47
+14.01% from price
SMA 100
5.32
+17.35% from price
SMA 200
5.04
+23.72% from price
EMA 12
5.87
+6.34% from price
EMA 26
5.68
+9.88% from price
EMA 50
5.54
+12.58% from price
RSI (14)
65.9
Neutral
MACD (12,26,9)
0.19
Hist 0.04
ATR (14)
0.27
4.34% of price
Realised vol 30D
51.1%
Annualised
Bollinger upper
6.44
20, 2σ
Bollinger lower
4.87
20, 2σ
50 / 200 cross
Golden
5.47 vs 5.04
Trend bias
Above 200
+23.72%
Risk profile
Beta vs SPY
2.14
More volatile than market
Correlation to SPY
0.46
Loosely linked
Realised vol 30D
51.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-32.2%
Peak to trough
Max drawdown 5Y
-82.1%
Peak to trough
ATR 14
0.27
4.34% of price
Beta (reported)
2.25
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
0.13
Positioning, not flow
Max pain
5.00
-19.9% from spot
ATM implied vol
58.6%
Nearest strike to spot
Skew (10% OTM)
+37.9%
Puts bid over calls
Call volume
16
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
5.00
25 contracts
Heaviest put OI
5.00
4 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Strata Critical Medical (SRTA) Q2 2026 Earnings Call Transcript
Motley Fool · 11d ago
Immersion Investment Views Strata Critical Medical (SRTA) as a “Babushka Doll”
Insider Monkey · 11d ago
Can Strata Critical Medical, Inc. (SRTA) Run Higher on Rising Earnings Estimates?
Zacks · 16d ago
Strata Critical Medical, Inc. Q2 2026 Earnings Call Summary
Moby · 18d ago
Strata Critical Medical Inc (SRTA) (Q2 2026) Earnings Call Highlights: Revenue Surges 60. ...
GuruFocus.com · 18d ago
Wall Street Analysts Predict a 60% Upside in Strata Critical Medical, Inc. (SRTA): Here's What You Should Know
Zacks · 18d ago
Strata Critical Medical Announces Second Quarter 2026 Results
GlobeNewswire · 18d ago
Strata Critical Medical Inc (SRTA) Q2 2026 Earnings Report Preview: What To Look For
GuruFocus.com · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.